Physician profile

Lazaro Diaz

Interventional Cardiology · Exeter, NH

NPI 1164495230

$14,946.82

in general payments reported to CMS, 2019-2025

37 companies · $1,197 in 2025

The $1,197 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

See the full distribution for Interventional Cardiology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,976.09
Travel and Lodging$847.50
Education$17.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Penumbra, INC. $5,105.90 2019-2025 Indigo System, Ruby Coil, Smart Coil
Inari Medical, INC. $3,183.27 2023-2025 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Boston Scientific Corporation $1,214.76 2019-2025 Latitude Communicator Power Supply, Lux-Dx Insertable Cardiac Monitor, Watchman Flx
Abiomed $951.28 2019-2025 Impella
Medtronic, INC. $800.28 2023-2024 Onyx Frontier, Hawkone, Venaseal
Amgen INC. $496.61 2019-2023 Repatha
Novartis Pharmaceuticals Corporation $308.83 2019-2025
Medtronic Vascular, INC. $304.00 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $295.44 2019-2020
Alnylam Pharmaceuticals INC. $258.78 2024-2025 Onpattro
Janssen Pharmaceuticals, INC $243.15 2019-2023 Xarelto
Abbott Laboratories $213.14 2019-2025 Cardiomems, Esprit
Shockwave Medical, INC $169.49 2023 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $141.84 2020-2024 Lifevest
Cvrx, INC. $141.32 2022
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Stryker Corporation $140.36 2025 Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit
Cardiovascular Systems INC. $114.16 2019-2023
Actelion Pharmaceuticals US, INC. $110.75 2019-2024 Opsumit, Uptravi
Pfizer INC. $97.58 2019-2025
Daiichi Sankyo INC. $91.84 2022-2023 Injectafer
Biotronik INC. $83.26 2019-2020
E.R. Squibb & Sons, L.L.C. $74.28 2019-2024 Camzyos, Eliquis
Lexicon Pharmaceuticals, INC. $61.27 2023-2024 Inpefa
Bayer Healthcare Pharmaceuticals INC. $47.68 2023-2024
Sanofi-Aventis U.S. LLC $39.89 2024
Quidel Corporation $33.96 2023 Triage
Regeneron Healthcare Solutions, INC. $25.84 2024 Evkeeza
Atricure, INC. $25.50 2023
Kestra Medical Technology Services, INC. $24.99 2024 Assure Wcd
Merck Sharp & Dohme LLC $23.62 2022
Portola Pharmaceuticals, LLC $22.60 2019
Novo Nordisk INC $20.14 2025 Wegovy
Astrazeneca Pharmaceuticals LP $18.35 2019
Lantheus Medical Imaging, INC. $17.95 2021
Vital Connect, INC $17.81 2024 Vitalpatch Rtm
Impulse Dynamics (USA) INC. $16.70 2023 Optimizer
Sensible Medical Innovations INC $10.20 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lazaro Diaz

$14,946.82

in general payments reported 2019-2025

Years
2019-2025
Top company
Penumbra, INC.
Context
The $1,197 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/143187/lazaro-diaz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.